1-Phenyl-2-bromo-2-(4-(methylsulfonyl)phenyl)ethanone → 2-(4-(Methylsulfonyl)phenyl)-3-phenylimidazo[2,1-b]thiazole
Reaction equation
[SH:1][C:2]1[NH:3][CH:4]=[CH:5][N:6]=1.[C:7]1([C:13](=O)[CH:14](Br)[C:15]2[CH:20]=[CH:19][C:18]([S:21]([CH3:24])(=[O:23])=[O:22])=[CH:17][CH:16]=2)[CH:12]=[CH:11][CH:10]=[CH:9][CH:8]=1>>[CH3:24][S:21]([C:18]1[CH:19]=[CH:20][C:15]([C:14]2[S:1][C:2]3=[N:6][CH:5]=[CH:4][N:3]3[C:13]=2[C:7]2[CH:12]=[CH:11][CH:10]=[CH:9][CH:8]=2)=[CH:16][CH:17]=1)(=[O:22])=[O:23]Participants
3
Procedure
Following the procedure of example 17, the title compound was prepared from 2-mercaptoimidazole and the bromoketone of step 3, example 1. 1H NMR (CDCl3): δ3.03 (s, 3H), 7.33 (d, 2H, J=3.5 Hz), 7.4-7.5 (m, 7H), 7.81 (d, 2H, J=8.4 Hz).
Sources & evidence
- ORD record
- ord-b312f1808124410f90bac1eaa1a978b4
- Source dataset
- uspto-grants-1996_09
- Patent number
- US05552422
Reaction notes
Loading…